Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Acquired by Two Sigma Advisers LP

Two Sigma Advisers LP raised its stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 11.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 156,300 shares of the biopharmaceutical company’s stock after acquiring an additional 15,700 shares during the period. Two Sigma Advisers LP owned approximately 0.27% of Vanda Pharmaceuticals worth $749,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in VNDA. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Vanda Pharmaceuticals during the fourth quarter valued at about $1,296,000. Millennium Management LLC boosted its stake in shares of Vanda Pharmaceuticals by 67.4% in the fourth quarter. Millennium Management LLC now owns 668,693 shares of the biopharmaceutical company’s stock valued at $3,203,000 after purchasing an additional 269,183 shares during the period. Susquehanna Fundamental Investments LLC purchased a new position in shares of Vanda Pharmaceuticals in the fourth quarter valued at approximately $1,221,000. Dimensional Fund Advisors LP boosted its stake in shares of Vanda Pharmaceuticals by 10.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,488,519 shares of the biopharmaceutical company’s stock valued at $11,920,000 after purchasing an additional 227,428 shares during the period. Finally, Monaco Asset Management SAM boosted its stake in shares of Vanda Pharmaceuticals by 92.8% in the fourth quarter. Monaco Asset Management SAM now owns 392,262 shares of the biopharmaceutical company’s stock valued at $1,879,000 after purchasing an additional 188,836 shares during the period. 88.14% of the stock is currently owned by institutional investors and hedge funds.

Vanda Pharmaceuticals Stock Down 0.9%

Shares of Vanda Pharmaceuticals stock opened at $4.30 on Tuesday. Vanda Pharmaceuticals Inc. has a 52-week low of $3.81 and a 52-week high of $6.75. The company has a 50 day moving average of $4.30 and a 200 day moving average of $4.57. The company has a market capitalization of $253.42 million, a P/E ratio of -13.44 and a beta of 0.69.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.05. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. The company had revenue of $50.04 million during the quarter, compared to the consensus estimate of $45.13 million. As a group, research analysts anticipate that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Mihael Hristos Polymeropoulos acquired 10,000 shares of the business’s stock in a transaction on Wednesday, March 5th. The shares were bought at an average price of $5.02 per share, with a total value of $50,200.00. Following the completion of the acquisition, the chief executive officer now owns 2,285,731 shares in the company, valued at $11,474,369.62. This trade represents a 0.44% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders bought 40,000 shares of company stock worth $178,600 over the last 90 days. 10.00% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. Wall Street Zen assumed coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They issued a “hold” rating for the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $13.00 price objective on shares of Vanda Pharmaceuticals in a research note on Wednesday, May 14th. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Vanda Pharmaceuticals in a research note on Wednesday, May 7th.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.